EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections

Benjamin August, Andrew Matlob iD, Pramodini B Kale-Pradhan iD

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231204566 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Benjamin August und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Henry Ford Hospital, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, …. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Sulbactam, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Data Sources: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514, ETX2514SUL. Study Selection and Data Extraction: Articles published in English between January 1985 and September 13, 2023, related to pharmacology, safety, efficacy, and clinical trials were reviewed. Data Synthesis: A phase II trial compared SUL-DUR with placebo with imipenem and cilastatin in both groups. Overall treatment success in the microbiological intention-to-treat analysis was reported in 76.6% of patients in the SUL-DUR group compared with 81% patients in the placebo group. A phase III trial compared SUL-DUR with colistin in adults with confirmed CRAB infections. Patients received either SUL-DUR or colistin and background therapy with imipenem-cilastatin. SUL-DUR was noninferior to colistin for 28-day all-cause mortality (19% vs 32.3%, treatment difference −13.2%; 95% CI [−30.0 to 3.5]). Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Clinicians have limited options to treat CRAB infections. SUL-DUR has demonstrated efficacy against CRAB in patients with pneumonia and may be considered a viable treatment option. Nonetheless, potential impact of concomitant imipenem-cilastatin as background therapy on clinical trial findings is unclear. Further studies are needed to elucidate the role of SUL-DUR alone or in combination with other active antimicrobials for the treatment of CRAB infections.

Conclusions

SUL-DUR has shown to be predominantly noninferior to alternative antibiotics in the treatment of pneumonias caused by CRAB, making it a viable treatment option. Further postmarketing data is needed to ascertain its role in other infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAcinetobacter InfectionsSulbactamAnti-Bacterial AgentsCarbapenemsAzabicyclo CompoundsHumansDrug Combinations

Stichwörter der Autor:innen

DurlobactamETX2514ETX2514SULSulbactamSulbactam-ETX2514Xacduro

Substanzen

SulbactamAnti-Bacterial AgentsCarbapenemsAzabicyclo CompoundsdurlobactamDrug Combinations

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Henry Ford Hospital, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
  • Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
  • Department of Pharmacy Practice, Ascension St. John Hospital, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.

ORCID-Profile: Andrew Matlob, Pramodini B Kale-Pradhan

Zitieren

APA

August, B., Matlob, A., & Kale-Pradhan, P. B. (2024). Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231204566

Vancouver

August B, Matlob A, Kale-Pradhan PB. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231204566

BibTeX
@article{August2024,
  author = {August, Benjamin and Matlob, Andrew and Kale-Pradhan, Pramodini B},
  title = {Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231204566}
}
Kostenlos starten →